Provenge infusion costs to be reimbursed but large sales boon unlikely
This article was originally published in Scrip
Executive Summary
The US Medicare and Medicaid health programmes have agreed to cover the infusions costs of Dendreon's prostate cancer vaccine Provenge (sipuleucel-T).